文献速递骨软组织肉瘤与黑色素瘤

晚期黑色素瘤患者短期联合靶向治疗与抗PD1后获得持久缓解:IMPemBra试验5年无进展生存与总生存更新

Durable responses upon short-term addition of targeted therapy to anti-PD1 in advanced melanoma patients: 5-year progression-free and overall survival update of the IMPemBra trial.
PubMed 文献 · Eur J Cancer · 2025-04-19

IMPemBra试验将32例初治BRAFV600E/K突变晚期黑色素瘤患者随机分为帕博利珠单抗单药组与联合间歇性达拉非尼+曲美替尼组,中位随访73个月,联合组5年PFS和OS数值上高于单药组,但部分联合方案3-4级免疫相关不良事件发生率较高,作者认为需在更大队列和随机设计中进一步分析。

要点

  • 中位随访73个月,帕博利珠单抗单药组5年PFS为25%、OS为50%。
  • 联合间歇靶向治疗组5年PFS为46%、OS为71%,数值上高于单药组。
  • 3-4级免疫相关不良事件发生率单药组12%,联合组12%至63%不等。

核心结论

  • IMPemBra试验的生存更新显示,短期靶向治疗与检查点抑制联合可诱导持久缓解,需在更大队列和随机设计中进一步分析。

研究设计与样本

  • IMPemBra试验将32例初治BRAFV600E/K突变晚期黑色素瘤患者先接受2周期帕博利珠单抗200 mg每3周一次,随后随机分为继续帕博利珠单抗单药6周(队列1)与帕博利珠单抗联合间歇性达拉非尼150 mg每日两次+曲美替尼2 mg每日一次,按2×1周(队列2)、2×2周(队列3)或1×6周(队列4)给药。
  • 第12周后所有患者继续帕博利珠单抗单药治疗最长2年。

主要发现

  • 中位随访73个月,最终3-4级免疫相关不良事件发生率:队列1为12%,队列2为12%,队列3为38%,队列4为63%。
  • 估计5年PFS和OS率:帕博利珠单抗单药组(队列1)为25%和50%,帕博利珠单抗+间歇靶向治疗组(队列2-4)为46%和71%。
  • 估计5年PFS和OS率分别为:队列2为63%和63%,队列3为38%和75%,队列4为38%和75%。
  • 后续治疗在各队列间均衡,接受短期/间歇方案的患者在后续靶向治疗时再次获得持久缓解。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者指出需在更大队列和随机设计中进一步分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The addition of targeted therapy (TT) to immune checkpoint inhibitors has been shown to transiently increase immune infiltration in melanoma. This formed the rationale for the IMPemBra trial, which showed a numerical increase in progression-free survival (PFS) in patients treated with short-term/intermittent TT and anti-PD1 compared to anti-PD1 alone. In this report, the final toxicity-analysis, 5-year PFS and exploratory analysis of overall survival (OS) will be reported, together with an analysis of subsequent therapies. PATIENTS AND METHODS: 32 treatment-naïve patients with a BRAFV600E/K-mutated advanced melanoma were treated with 2 cycles of pembrolizumab 200 mg every 3 weeks, followed by randomization to continue pembrolizumab monotherapy for six weeks in cohort-1 versus pembrolizumab plus intermittent dabrafenib 150 mg BID + trametinib 2 mg QD 2×1-week (cohort 2), 2×2-weeks (cohort 3), or 1×6-weeks (cohort 4). After week 12, all patients continued pembrolizumab monotherapy for a maximum of 2 years. RESULTS: With a median follow-up of 73 months, final grade 3-4 immune-related adverse events are 12 % (cohort 1), 12 % (cohort 2), 38 % (cohort 3) and 63 % (cohort 4). Estimated 5-year PFS and OS rates were 25 % and 50 % for pembrolizumab monotherapy (cohort-1) and 46 % and 71 % for pembrolizumab + intermittent TT (cohorts 2-4). Estimated 5-year PFS and OS were 63 % and 63 % (cohort 2), 38 % and 75 % (cohort 3), and 38 % and 75 % (cohort 4), respectively. The subsequent therapies were balanced between cohorts. Patients treated with short-term/intermittent schemes achieved durable responses upon subsequent TT again. CONCLUSION: This survival update from the IMPemBra trial demonstrates that combination of short-term TT and checkpoint inhibition can induce long-lasting responses, warranting further analyses in larger cohorts, and in a randomized design.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Hoeijmakers LL, Rozeman EA, Lopez-Yurda M, et al. Durable responses upon short-term addition of targeted therapy to anti-PD1 in advanced melanoma patients: 5-year progression-free and overall survival update of the IMPemBra trial. Eur J Cancer. 2025. PMID: 40279684. doi:10.1016/j.ejca.2025.115431

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。